Literature DB >> 6329082

Cefmenoxime therapy of serious bacterial infections.

M E Gombert, L A Glasser, R H Eng.   

Abstract

The efficacy and safety of cefmenoxime was evaluated in 50 patients with serious bacterial infections. These included 26 pneumonias, 18 urinary tract infections, 2 soft tissue infections, 2 bacteremias, 1 renal abscess, and 1 peritonitis. A satisfactory clinical response was seen in 47 patients (94%). Eosinophilia and thrombocytosis were seen in several patients but were generally mild and transient.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6329082      PMCID： PMC185566          DOI： 10.1128/AAC.25.4.510

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  Comparative in vitro activities of cefmenoxime (SCE-1365) and newer cephalosporin derivatives of clinical utility.

Authors:  V I Ahonkhai; C E Cherubin; M A Shulman; U Bancroft
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

2.  Comparative in vitro susceptibilities of anaerobic bacteria to cefmenoxime, cefotetan, and N-formimidoyl thienamycin.

Authors:  W E Owens; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

3.  Susceptibilities of anaerobic bacteria to N-formimidoyl thienamycin (MK0787) and to other antibiotics.

Authors:  T Kesado; K Watanabe; Y Asahi; M Isono; K Ueno
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

4.  Comparative in vitro activity of new beta-lactam antibiotics against anaerobic bacteria.

Authors:  R D Rolfe; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

5.  In vitro activity and beta-lactamase stability of cefmenoxime.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

6.  Moxalactam therapy for bacterial infections.

Authors:  D J Winston; R W Busuttil; T O Kurtz; L S Young
Journal:  Arch Intern Med       Date:  1981-11
  6 in total
  3 in total

1.  Levels of cefmenoxime in sera and peritoneal tissues of patients undergoing gastrointestinal surgery.

Authors:  R Doi; K Inoue; K Hara; T Tobe
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

Review 2.  Treatment of respiratory tract infections with cephalosporin antibiotics.

Authors:  R Finch
Journal:  Drugs       Date:  1987       Impact factor: 9.546

3.  Clinical efficacy and safety of cefmenoxime in children.

Authors:  G F Tansino; M R Hammerschlag; B L Congeni; P A Cox; B Doraiswamy; L duBouchet
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.